NCT03832426View on ClinicalTrials.gov

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 8, 2013

Primary Completion Date

October 24, 2014

Study Completion Date

October 24, 2014

Conditions
Hepatic Impairment
Interventions
DRUG

Narlaprevir

100 mg film-coated tablets

DRUG

Ritonavir

100 mg film-coated tablets

Trial Locations (3)

Unknown

LLC Chapidze Emergency Cardiology Center, Tbilisi

LLC Guli (Heart) - Cardiology clinic, Tbilisi

"- Institution of the Russian Academy of Sciences RAS Hospital", Troitsk

Sponsors

Lead Sponsor

R-Pharm

Collaborators (1)

Ascent
All Listed Sponsors
collaborator

Ascent

UNKNOWN

lead

R-Pharm

INDUSTRY

NCT03832426 - A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers | Biotech Hunter | Biotech Hunter